Match!
Karen Ansaldo
CisplatinParicalcitolPancreatic cancerGemcitabineMedicine
8Publications
3H-index
30Citations
What is this?
Publications 8
Newest
#1Gayle S. Jameson (TGen: Translational Genomics Research Institute)H-Index: 14
#2Erkut Borazanci (TGen: Translational Genomics Research Institute)H-Index: 10
Last. Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 86
view all 16 authors...
Importance Genomes of metastatic pancreatic cancers frequently contain intrachromosomal aberrations, indicating a DNA repair deficiency associated with sensitivity to DNA damaging agents, such as platinum. Objective To determine response rate following treatment with nab-paclitaxel plus gemcitabine plus platinum-based cisplatin for patients with metastatic pancreatic ductal adenocarcinoma (PDA). Design, Setting, and Participants This was a single-arm, open-label, phase 1b/2 clinical trial of nab...
4 CitationsSource
#1Gayle S. JamesonH-Index: 14
#2Erkut BorazanciH-Index: 10
Last. Daniel D. Von HoffH-Index: 86
view all 10 authors...
Introduction: Based on the unmet medical need in MPC, its high frequency of Ras mutations, and prior work combining PP + C + G demonstrating an objective response rate of 70.5% in 24 pts with MPC with a median survival of 16.4 mos (J Clin Oncol 2017;35 [suppl 4S; abstract 341]), we are exploring the addition of HD AA to PP + C + G (#NCT03410030). Background: Increasing evidence suggests that HD AA (vitamin C) can decrease the growth of aggressive tumors, including Ras-mutant tumors, by inducing ...
Source
#1Erkut BorazanciH-Index: 10
#2Gayle S. JamesonH-Index: 14
Last. Daniel D. Von HoffH-Index: 86
view all 9 authors...
Background: Effective therapy for the treatment of PDAC remains one of the greatest unmet oncology clinical needs. The addition of C to G and AP has shown promising clinical data in a previously reported study [J Clin Oncol 35, 2017 (suppl 4S; abstract 341)]. In preclinical work, vitamin D (Vit D) analog therapy decreases myeloid derived suppressor cells and regulatory T cells, favorably influencing the immune environment. This trial combines AP/C/G with Vit D analog P and the anti-PD-1 antibody...
Source
#1Vincent Chung (City of Hope National Medical Center)H-Index: 17
#2Erkut Borazanci (TGen: Translational Genomics Research Institute)H-Index: 10
Last. Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 86
view all 20 authors...
TPS4154Background: Pancreatic cancer remains a deadly disease and despite advances in chemotherapy treatment, survival for most patients is still less than one year. Refractory pancreatic cancer ha...
1 CitationsSource
#1Gayle S. JamesonH-Index: 14
#2Erkut BorazanciH-Index: 10
Last. Daniel D. Von HoffH-Index: 86
view all 15 authors...
341Background: Genomes of metastatic pancreatic cancers frequently contain intrachromosomal aberrations indicating DNA repair abnormalities associated with sensitivity to DNA damaging agents such as the platinums. Cisplatin was added to a nab-paclitaxel + gemcitabine regimen, which has been determined to improve survival over gemcitabine alone (NEJM 2013; 369:1691-1703). The objectives are to determine the efficacy and safety of nab-paclitaxel and gemcitabine plus cisplatin in patients with Stag...
10 CitationsSource
#1Erkut Borazanci (TGen: Translational Genomics Research Institute)H-Index: 10
#2Gayle S. JamesonH-Index: 14
Last. Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 86
view all 9 authors...
TPS511Background: Despite decades of basic and clinical research, effective therapy for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) remains one of the greatest unmet clinical needs in oncology today. Albumin-bound paclitaxel (AP) and gemcitabine (G) reported on an improvement in overall survival in metastatic (m) PDAC [NEJM 2013; 369:1691-1703]. The addition of cisplatin (C) has shown promising clinical data in previously reported studies [Cancer Res 2015; 75(15 Suppl)...
7 CitationsSource
#1Gayle S. JamesonH-Index: 14
#2Erkut BorazanciH-Index: 10
Last. Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 86
view all 13 authors...
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Background: The genomes of metastatic pancreatic cancers contain a myriad of intrachromosomal aberrations indicating a likely high prevalence of DNA repair deficiencies indicating sensitivity to DNA damaging agents such as the platinum’s. Because of this, the drug cisplatin was added to an albumin-bound paclitaxel + gemcitabine regimen, which has already been determined to improve survival over gemcitabine alone in ...
2 CitationsSource
#1Mitesh J. Borad (TGen: Translational Genomics Research Institute)H-Index: 34
#2Arundhati D Soman (Mayo Clinic)H-Index: 2
Last. Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 86
view all 11 authors...
A retrospective analysis of 130 patients was conducted in a Phase I oncology clinic to assess the effect of QTc formula selection on clinical trial eligibility. QTc values were calculated from screening electrocardiograms using 7 formulae (Bazett, Fridericia, Framingham, Hodges, Mayeda, Van de Water and Wohlfart). QTc values > 470 ms for females and > 450 ms for males were used to define prolongation. Concomitant medication potential for QTc prolongation was determined using a public database (A...
2 CitationsSource
1